Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model

Table 1 Effect of erlotinib treatment on microscopic damage score (means ± SE, n = 10-20)

	Loss of mucosal architecture	Cell infiltration	Muscle thickness	Goblet cell depletion	Crypt abscess formation	Total microscopic score
Proximal
Normal	0.67 ± 0.19	1.58 ± 0.23	0.83 ± 0.11	0.83 ± 0.11	0.33 ± 0.14	4.25 ± 0.55
Vehicle	1.40 ± 0.16b	2.50 ± 0.12b	1.60 ± 0.22a	1.00 ± 0.00	0.80 ± 0.13	7.50 ± 0.27b
Erlotinib	1.40 ± 0.11b	2.35 ± 0.11b	1.55 ± 0.17a	1.00 ± 0.00	0.60 ± 0.11	6.90 ± 0.27b
Mid
Normal	0.75 ± 0.18	1.50 ± 0.67	0.92 ± 0.29	0.83 ± 0.39	0.45 ± 0.51	4.42 ± 0.51
Vehicle	1.50 ± 0.22a	2.70 ± 0.15b	2.00 ± 0.26b	1.00 ± 0.00	0.70 ± 0.15	7.90 ± 0.53b
Erlotinib	1.50 ± 0.14b	2.35 ± 0.49b	1.85 ± 0.59b	1.00 ± 0.00	0.45 ± 0.51	7.15 ± 0.31b
Distal
Normal	1.08 ± 0.26	1.92 ± 0.23	1.50 ± 0.19	0.92 ± 0.08	0.25 ± 0.13	5.67 ± 0.66
Vehicle	1.80 ± 0.20	2.70 ± 0.15a	2.20 ± 0.20b	1.00 ± 0.00	0.50 ± 0.11	8.20 ± 0.49b
Erlotinib	2.05 ± 0.15b	2.50 ± 0.14a	2.45 ± 0.14b	1.00 ± 0.00	0.75 ± 0.10a	8.75 ± 0.32b

Vehicle is methyl cellulose. One-way analysis of variance between groups.

^aP < 0.05,

^bP < 0.01 vs normal animals within the same colonic region.